WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the
“Company”), a clinical-stage, specialty pharmaceutical company with two platform technologies for treating diseases and disorders
of the eye, has completed enrollment in the double-masked, randomized, placebo-controlled Phase 2b trial of its EGP-437 combination
product for the treatment of pain and inflammation in patients having undergone cataract surgery. Topline data is expected to be
released in the first quarter of 2018.
As a result, EyeGate has received an additional milestone payment under its licensing agreement with a subsidiary of Valeant
Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX) (“Valeant”).
The study has enrolled a total of 100 subjects at eight clinical sites across the United States.
The trial is intended to assess the safety and efficacy of transscleral iontophoretically-delivered EGP-437 through the Company’s
EyeGate® II Delivery System in patients that have undergone cataract surgery with implantation of a monofocal posterior chamber
IOL. The primary efficacy endpoint of the study is the proportion of subjects with an anterior chamber (AC) cell count of zero at
day 7 and the proportion of subjects with pain score of zero at day 1.
“This is an important milestone for EyeGate and we are eagerly looking forward to proceeding with the next steps and expect to
report results early first quarter next year,” commented Barbara Wirostko, M.D., Chief Medical Officer of EyeGate. “Cataract
surgery is among the top eye surgical procedures performed every year, with over four million in the U.S. alone. EGP-437
seeks to reduce patient non-compliance issues and produce better outcomes by potentially eliminating the need for post-operative
anti-inflammatory eye drops.”
In February 2017, EyeGate entered into an exclusive, worldwide licensing agreement through which EyeGate granted Valeant
exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product candidate for the treatment of
post-operative ocular inflammation and pain in ocular surgery patients. Upon FDA approval, Valeant expects to market the
combination product through its Bausch + Lomb Pharmaceuticals business.
About EyeGate
EyeGate is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products using its two
proprietary platform technologies for treating diseases and disorders of the eye.
EyeGate’s most advanced platform is based on a cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form
of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as
hydrating and healing when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist
degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries.
EGP-437, EyeGate’s other product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone
Phosphate, that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II
Delivery System. www.EyeGatePharma.com.
EyeGate Social Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page, corporate Twitter account, and LinkedIn page as channels of distribution of information about EyeGate and its product
candidates. Such information may be deemed material information, and EyeGate may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should monitor EyeGate’s website and its social media accounts in addition to
following its press releases, SEC filings, public conference calls, and webcasts. The social media channels that EyeGate
intends to use as a means of disclosing the information described above may be updated from time to time as listed on EyeGate’s
investor relations website.
Forward-looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the
Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other
things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate’s products,
including EyeGate’s EGP-437 combination product and those of Jade Therapeutics, Inc., a wholly owned subsidiary of EyeGate, as well
as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These
statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press
release, including, among other things, certain risk factors described under the heading “Risk Factors” contained in our Annual
Report on Form 10-K filed with the SEC on February 23, 2017 or described in EyeGate’s other public filings. EyeGate’s results may
also be affected by factors of which EyeGate is not currently aware. The forward-looking statements in this press release speak
only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events,
conditions or circumstances on which any such statement is based.
Contact:
Lee Roth / Janhavi Mohite
The Ruth Group for EyeGate Pharmaceuticals
646-536-7012 / 7026
lroth@theruthgroup.com / jmohite@theruthgroup.com
